1. Receptor tyrosine kinase inhibitors cause dysfunction in adult rat cardiac fibroblasts in vitro
- Author
-
Robert Walmsley, Tim S. Munsey, Matthew J. Burke, and Andrew J. Smith
- Subjects
Male ,0301 basic medicine ,Cell Survival ,Pharmacology ,Toxicology ,03 medical and health sciences ,0302 clinical medicine ,Sunitinib ,medicine ,Animals ,Viability assay ,Rats, Wistar ,Protein Kinase Inhibitors ,Cells, Cultured ,Cell Proliferation ,biology ,business.industry ,Myocardium ,Imatinib ,General Medicine ,Fibroblasts ,Sunitinib malate ,Rats ,030104 developmental biology ,Imatinib mesylate ,030220 oncology & carcinogenesis ,Toxicity ,Imatinib Mesylate ,biology.protein ,Cytokines ,business ,Tyrosine kinase ,Platelet-derived growth factor receptor ,medicine.drug - Abstract
The anti-cancer receptor tyrosine kinase inhibitors include known cardiotoxins: a component of this toxicity may be mediated by effects on cardiac fibroblasts (CFs). We hypothesised that imatinib mesylate (imatinib) and sunitinib malate (sunitinib) cause significant dysfunction in adult CFs. Following in vitro treatments with imatinib or sunitinib, adult rat CF viability was assessed by fluorescein diacetate assay, proliferation measured by bromodeoxyuridine nuclear incorporation and changes to the expression of CF secretome components determined by real time quantitative RT-PCR. Imatinib and sunitinib significantly reduced cell viability over 48 h, with EC50 values of 11.0 μM (imatinib) and 4.5 μM (sunitinib) respectively. Imatinib reduced CF proliferation from 35.5 ± 3.2% in control to 23.0 ± 5.5% (3 μM; p
- Published
- 2019
- Full Text
- View/download PDF